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years, including EPID-based Winston Lutz tests, table rotation 
inaccuracy measurements, leaf and jaw position accuracies 
and kV-MV isocenter measurements.  
 
Results: Table 1 summarizes the precision of the separate 
elements in our intracranial SRS treatment chain. The largest 
inaccuracies of about a mm are found for imaging, 
delineation and treatment planning. Image registration, 
machine QA and patient setup show high sub mm accuracy. 
Resulting accuracies are in compliance with the SRS 
tolerances as mentioned in international and national 
guidelines (AAPM TG 142, NCS 22 and 24). The TPS dose grid 
will be adjusted to 2 mm (recommendation by AAPM TG 101). 
Furthermore, setup and image registration data are in good 
agreement with literature [1]. In addition to the upper 
tolerance limits from guidelines, this table provides detailed 
reference material regarding realistic machine and treatment 
accuracies for frameless, linac-based intracranial SRS. 
 
 
 
Conclusion: This method to comprehensively map and 
evaluate SRS treatment accuracy has allowed us to identify 
the most relevant sources of treatment delivery uncertainties 
and indicate items that require further investigation. 
Currently, relevant treatment uncertainties are further 
investigated and an end-to-end test is developed to further 
define and improve our accuracy. This approach can be 
extended to other stereotactic sites and techniques as well 
as to other institutes. We believe that comparing this kind of 
comprehensive data over institutes will also help to improve 
evaluation of treatment outcome as the actually delivered 
dose highly depends on the treatment accuracy. 
[1] Seravalli E. et al., Radiotherapy and Oncology, 2015, 
Vol.116(1); pp. 131-8. 
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Purpose or Objective: To demonstrate the feasibility of 
using a statistical algorithm, MDC-OVER-UNDER, as an 
automated assessment tool of a test case for radiotherapy 
outlining. If feasible, this efficient technique could be used 
to screen submissions for significant errors in outlining a 
radiotherapy quality assurance (RTTQA) pre-trial test case. 
 
Material and Methods: UK centres submitted a neoadjuvant 
radiotherapy rectal cancer test case, prior to recruitment to 
the phase III ARISTOTLE trial. CERR (a computational 
environment for radiotherapy research) software platform 
was used for assessment. Previous pilot work using 
conformity indices to evaluate target volume delineation 
(TVD) in this trial had limitations. An MDC value of +/- 0.2mm 
from a single line reference volume calculated from ROC 
curve analysis, gave high sensitivity and specificity for slices 
which were over/under outlined. We were unable to 
satisfactorily validate this system owing to areas of 
“accepted” discrepancy from the reference standard (RS). In 
this work, a RS (non-margin generated) CTV with a minimum 
and maximum extent was created by two clinicians involved 
in the RTTQA process (fig 1). This was based on previous 
single line RS and iterative review of submissions from 
several centres. MDC-OVER-UNDER on a slice by slice basis, 
was applied to the individual institution submitted CTV. For 
any slice of the volume to pass the automated assessment, 
both following criteria had to be met. NB. An outline 
difference of 0.1mm is visually perfect.  
1) For CTV MAX extent: MDC Over (mm) - 0.1mm = ≤ 
0mm 2) For CTV MIN extent: MDC Under (mm) + 
0.1mm = ≥0mm. 
 
 
 
Results: We analysed 16 submissions from 10 centres. Data 
was saved in CERR format with uniform naming convention. 
The RS CTV ranged from maximum extent slices 30-53 (24 
slices); minimum extent slices 31-52 (22 slices). Assessment 
of a submission was complete within seconds. The algorithm 
identified and quantified deviation for every outlined slice as 
expected. There was a quantifiable improvement in TV 
delineation in 75% of centres who had more than one 
submission, post feedback. Extra/missing slices were always 
associated with an MDC value greater then +/- 0.5mm 
respectively. Superior and inferior portions of the volume 
showed most discordance as reflected in the MDC values, 
with a tendency to over outline superiorly. Data was simply 
presented in Excel (see table) for review by centre and 
reviewer, highlighting and quantifying slices for revision. 
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Conclusion: The MDC-OVER-UNDER analysis as an assessment 
tool, has the potential to reduce labour, reduce inter/intra 
observer variability and provide rapid quantified feedback. 
Consistently failing volumes would trigger protocol review in 
the first instance. Wider application in an RTTQA or 
educational setting requires a consensus min/max extent 
volume for several operator defined volumes by the TMG 
from the outset, supported by the STAPLE algorithm. 
(Excluding spaces <2500 characters on word.) 
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Purpose or Objective: The TRENDY trial is an international 
multi-center phase II study in which patients with 
hepatocellular carcinoma (HCC) are randomized between 
transarterial chemoembolization in the standard arm and 
stereotactic body radiation therapy (SBRT) in the 
experimental arm. SBRT is delivered in six fractions with a 
total target dose of 48-54 Gy. Since the treatment is 
technologically challenging, an extensive quality assurance 
(QA) program has been established. The main goal is to 
ensure high quality treatments in order to achieve an optimal 
clinical outcome. 
 
Material and Methods: QA guidelines and recommendations 
are outlined in a separate QA protocol, which also defines 
minor and major protocol deviations. Treatment is not 
allowed with a major deviation. If possible minor deviations 
must be avoided. Centers can only start entering patients 
with a successfully completed external dosimetry audit. Prior 
to patient inclusion, a QA questionnaire should be filled out 
with regards to imaging modalities, treatment planning, 
patient setup, margins, breathing-motion management and 
treatment delivery. Besides that, centers are requested to 
complete a dummy run, including contouring and treatment 
planning. Contours are evaluated by comparison with golden 
contours, based on consensus within an expert panel. 
Treatment plans are evaluated using the constraints and 
objectives outlined in the treatment protocol, including an 
NTCP for the healthy liver. During patient accrual, the QA 
protocol accommodates prospective feedback for the first 
patients from each center. 
 
Results: Ten participating institutes completed and 
submitted the dummy-run. All contours were considered 
acceptable, although variation in both liver and GTV contours 
was substantial as shown in the figure below. Both individual 
feedback and general recommendations regarding 
delineations have been provided. The results of the 
treatment planning round are summarized in the table below. 
Two centers (III and VII) did not meet the NTCP constraint 
initially and re-planned the dummy-run patient after 
feedback had been provided. Dose homogeneity and 
conformity vary substantially, with some institutes aiming at 
a high target dose allowing for large dose gradients in the 
GTV-PTV margin, and others optimizing for a smoother, more 
homogeneous, dose distribution. 
 
 
 
Above: Axial slices with liver (left) and GTV (right) contours 
of the participating institutes. Below: Protocol requirements 
and planning dummy-run results. Roman numbers (I, II, …) 
refer to the institutes and replannings are indicated with an 
asterisk (*). 
 
Conclusion: As part of the TRENDY randomized trial, an 
extensive QA program has been implemented including a 
dummy run. Individual feedback and general 
recommendations have been provided to the participating 
centers, and will continue to be provided while patients are 
included. 
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Purpose or Objective: To develop and assess methodologies 
necessary for baseline alignment and dosimetry 
measurements for a fixed horizontal radiation beam as may 
occur in heavy ion and proton facilities and is the case for 
the Australian MRI-linac program (AMP) 
 
Material and Methods: The AMP utilises a fixed horizontal 
beam which is parallel to the magnetic field. To maximise 
flexibility the entire linac system (a linatron and independent 
millennium MLC system, Varian Inc) can be moved on a rail 
